

# George Thomas

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2986919/george-thomas-publications-by-year.pdf>

**Version:** 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

12,116  
citations

40  
h-index

56  
g-index

56  
ext. papers

13,292  
ext. citations

13.5  
avg, IF

5.8  
L-index

#	Paper	IF	Citations
54	Sexual Dysfunction in Schizophrenia: A Narrative Review of the Mechanisms and Clinical Considerations. <i>Psychiatry International</i> , <b>2022</b> , 3, 29-42	0.8	0
53	Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis. <i>EMBO Journal</i> , <b>2020</b> , 39, e105111	13	9
52	Nucleotide depletion reveals the impaired ribosome biogenesis checkpoint as a barrier against DNA damage. <i>EMBO Journal</i> , <b>2020</b> , 39, e103838	13	9
51	Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content. <i>Cancer Research</i> , <b>2019</b> , 79, 4348-4359	10.1	11
50	Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3767-3780	12.9	13
49	Mitochondrial Complex I Activity Is Required for Maximal Autophagy. <i>Cell Reports</i> , <b>2018</b> , 24, 2404-2417.e8	10.6	48
48	Ribosome biogenesis in cancer: new players and therapeutic avenues. <i>Nature Reviews Cancer</i> , <b>2018</b> , 18, 51-63	31.3	276
47	A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. <i>Targeted Oncology</i> , <b>2017</b> , 12, 323-332	5	61
46	Autogenous Control of 5'TOP mRNA Stability by 40S Ribosomes. <i>Molecular Cell</i> , <b>2017</b> , 67, 55-70.e4	17.6	49
45	Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF- $\beta$ signaling and malignant features and. <i>Oncotarget</i> , <b>2017</b> , 8, 114856-114876	3.3	24
44	Effect of low doses of actinomycin D on neuroblastoma cell lines. <i>Molecular Cancer</i> , <b>2016</b> , 15, 1	42.1	48
43	S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. <i>Nature Immunology</i> , <b>2016</b> , 17, 514-522	19.1	45
42	S6K1 Phosphorylation of H2B Mediates EZH2 Trimethylation of H3: A Determinant of Early Adipogenesis. <i>Molecular Cell</i> , <b>2016</b> , 62, 443-452	17.6	49
41	A liaison between mTOR signaling, ribosome biogenesis and cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , <b>2015</b> , 1849, 812-20	6	72
40	V-ATPase: a master effector of E2F1-mediated lysosomal trafficking, mTORC1 activation and autophagy. <i>Oncotarget</i> , <b>2015</b> , 6, 28057-70	3.3	36
39	Loss of tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity. <i>Molecular and Cellular Biology</i> , <b>2013</b> , 33, 4660-71	4.8	67
38	5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. <i>Cell Reports</i> , <b>2013</b> , 4, 87-98	10.6	165

37	Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth. <i>PLoS ONE</i> , <b>2013</b> , 8, e54221	3.7	57
36	Metabolic control by S6 kinases depends on dietary lipids. <i>PLoS ONE</i> , <b>2012</b> , 7, e32631	3.7	15
35	Phospholipase D and mTORC1: nutrients are what bring them together. <i>Science Signaling</i> , <b>2012</b> , 5, pe13	8.8	25
34	mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 139ra84	17.5	76
33	Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. <i>Genes and Development</i> , <b>2012</b> , 26, 1028-40	12.6	134
32	A matter of energy stress: p38 $\beta$ meets mTORC1. <i>Cell Research</i> , <b>2011</b> , 21, 859-61	24.7	3
31	Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. <i>Cancer Research</i> , <b>2011</b> , 71, 3669-75	10.1	16
30	Research and innovation in the development of everolimus for oncology. <i>Expert Opinion on Drug Discovery</i> , <b>2011</b> , 6, 323-38	6.2	22
29	mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. <i>Science</i> , <b>2010</b> , 328, 1172-6	33.3	538
28	Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 1576-81	11.5	100
27	The nuclear receptor DHR3 modulates dS6 kinase-dependent growth in Drosophila. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1000937	6	15
26	S6K1 plays a critical role in early adipocyte differentiation. <i>Developmental Cell</i> , <b>2010</b> , 18, 763-74	10.2	145
25	Phosphatase 2A puts the brakes on mTORC1 nutrient signaling. <i>Cell Metabolism</i> , <b>2010</b> , 11, 245-7	24.6	1
24	Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. <i>Cell Metabolism</i> , <b>2010</b> , 11, 390-401	24.6	631
23	Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. <i>Journal of Cell Biology</i> , <b>2009</b> , 187, 859-74	7.3	260
22	Tubers and tumors: rapamycin therapy for benign and malignant tumors. <i>Current Opinion in Cell Biology</i> , <b>2009</b> , 21, 230-6	9	38
21	Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. <i>Science</i> , <b>2009</b> , 326, 140-4	33.3	866
20	Differential requirement of mTOR in postmitotic tissues and tumorigenesis. <i>Science Signaling</i> , <b>2009</b> , 2, ra2	8.8	55

19	mTOR, cancer and transplantation. <i>American Journal of Transplantation</i> , <b>2008</b> , 8, 2212-8	8.7	88
18	Amino acids activate mTOR complex 1 via Ca <sup>2+</sup> /CaM signaling to hVps34. <i>Cell Metabolism</i> , <b>2008</b> , 7, 456-61	14.6	301
17	Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1596-602	2.2	192
16	Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 1237-45	6.1	110
15	Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. <i>Learning and Memory</i> , <b>2008</b> , 15, 29-38	2.8	106
14	Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 3065-74	15.9	1031
13	Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 14056-61	11.5	336
12	mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. <i>Trends in Molecular Medicine</i> , <b>2007</b> , 13, 252-9	11.5	389
11	Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. <i>Annals of Neurology</i> , <b>2006</b> , 59, 490-8	9.4	494
10	Hypothalamic mTOR signaling regulates food intake. <i>Science</i> , <b>2006</b> , 312, 927-30	33.3	973
9	The amino acid sensitive TOR pathway from yeast to mammals. <i>FEBS Letters</i> , <b>2006</b> , 580, 2821-9	3.8	169
8	The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. <i>Cell</i> , <b>2005</b> , 120, 747-59	56.2	435
7	Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 14238-43	11.5	622
6	Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. <i>Molecular and Cellular Biology</i> , <b>2004</b> , 24, 6231-40	4.8	96
5	S6K1(-)/S6K2(-) mice exhibit perinatal lethality and rapamycin-sensitive 5'Terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. <i>Molecular and Cellular Biology</i> , <b>2004</b> , 24, 3112-24	4.8	623
4	Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. <i>Cancer Research</i> , <b>2004</b> , 64, 252-61	10.1	302
3	Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. <i>Molecular and Cellular Biology</i> , <b>2004</b> , 24, 9508-16	4.8	375
2	Phytohormones participate in an S6 kinase signal transduction pathway in Arabidopsis. <i>Plant Physiology</i> , <b>2004</b> , 134, 1527-35	6.6	97

- 1 Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature*, **2004**, 431, 200-5 50.4 1341